Lander Heather L, Ejiofor Julius I, McGurk Siobhan, Tsuyoshi Kaneko, Shekar Prem, Body Simon C
Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts.
Division of Cardiac Surgery, Department of Surgery, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts.
Ann Thorac Surg. 2017 Feb;103(2):497-503. doi: 10.1016/j.athoracsur.2016.10.020. Epub 2016 Dec 24.
Deep sternal wound infection (DSWI) is a devastating complication that increases morbidity and death in cardiac surgical patients. Vancomycin is often administered intravenously for antibiotic prophylaxis in cardiac operations. Many cardiac surgeons also apply vancomycin paste topically to the sternal edges. We examined the effect of vancomycin paste on the incidence of DSWI in patients undergoing elective cardiac operations.
We retrospectively reviewed the medical records of all patients from 2003 to 2015 who underwent coronary artery bypass grafting, valve, or combined coronary artery bypass grafting and valve operations at a single institution. We derived The Society for Thoracic Surgeons (STS) DSWI risk index for each patient and systematically reviewed operative, pharmacy, microbiology, and discharge records to document DSWI in these patients. Multivariate analyses were used to identify predictors of DSWI in this cohort and to quantify the effect of vancomycin paste.
Of the 14,492 patients whose records we examined, DSWI developed in 136 patients, resulting in an overall incidence of 0.9%. After multivariate analysis, body mass index, New York Heart Association Functional Classification, and the STS DSWI risk index remained statistically significant and associated with DSWI. Although the incidence of DSWI decreased over time, the use of vancomycin paste was not associated with a reduced incidence of DSWI.
There was a marked decrease in the incidence of DSWI during the study period, concurrent with institutional implementation of revised STS antibiotic dosing guidelines in 2007 and other strategies. However, the application of vancomycin paste to the sternal edges of patients undergoing cardiac operations was not associated with a reduced risk of DSWI.
深部胸骨伤口感染(DSWI)是一种极具破坏性的并发症,会增加心脏手术患者的发病率和死亡率。万古霉素常用于心脏手术中的抗生素预防。许多心脏外科医生还会在胸骨边缘局部涂抹万古霉素糊剂。我们研究了万古霉素糊剂对择期心脏手术患者DSWI发生率的影响。
我们回顾性分析了2003年至2015年在单一机构接受冠状动脉搭桥术、瓣膜手术或冠状动脉搭桥术与瓣膜联合手术的所有患者的病历。我们为每位患者计算了胸外科医师协会(STS)DSWI风险指数,并系统回顾了手术、药房、微生物学和出院记录,以记录这些患者中的DSWI情况。多变量分析用于确定该队列中DSWI的预测因素,并量化万古霉素糊剂的效果。
在我们检查的14492例患者中,136例发生了DSWI,总体发生率为0.9%。多变量分析后,体重指数、纽约心脏协会功能分级和STS DSWI风险指数仍具有统计学意义,且与DSWI相关。尽管DSWI的发生率随时间下降,但万古霉素糊剂的使用与DSWI发生率的降低无关。
在研究期间,DSWI的发生率显著下降,这与2007年机构实施修订后的STS抗生素给药指南及其他策略同时发生。然而,在心脏手术患者的胸骨边缘涂抹万古霉素糊剂与降低DSWI风险无关。